Insmed/$INSM
14:30
22:10
05:45
13:25
21:00
1D1W1MYTD1Y5YMAX
About Insmed
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Ticker
$INSM
Sector
Primary listing
Employees
1,271
Headquarters
Website
Insmed Metrics
BasicAdvanced
$40B
-
-$6.22
1.03
-
Price and volume
Market cap
$40B
Beta
1.03
52-week high
$197.08
52-week low
$60.40
Average daily volume
2.1M
Financial strength
Current ratio
4.63
Quick ratio
4.183
Long term debt to equity
77.493
Total debt to equity
78.274
Interest coverage (TTM)
-11.81%
Profitability
EBITDA (TTM)
-978.79
Gross margin (TTM)
76.54%
Net profit margin (TTM)
-264.83%
Operating margin (TTM)
-221.53%
Effective tax rate (TTM)
-0.40%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-28.05%
Return on equity (TTM)
-165.69%
Valuation
Price to revenue (TTM)
79.299
Price to book
41.87
Price to tangible book (TTM)
52.85
Price to free cash flow (TTM)
-39.12
Free cash flow yield (TTM)
-2.56%
Free cash flow per share (TTM)
-4.76
Growth
Revenue change (TTM)
30.34%
Earnings per share change (TTM)
11.82%
3-year revenue growth (CAGR)
22.67%
3-year earnings per share growth (CAGR)
19.60%
10-year earnings per share growth (CAGR)
12.67%
What the Analysts think about Insmed
Analyst ratings (Buy, Hold, Sell) for Insmed stock.
Bulls say / Bears say
The FDA approved Brinsupri (brensocatib) on August 12, 2025 as the first and only treatment for non-cystic fibrosis bronchiectasis, addressing an unmet need in 350,000–500,000 U.S. patients (Reuters)
Analysts project peak U.S. sales of $3.7 billion for Brinsupri by 2031, signaling substantial long-term revenue potential for Insmed’s newly approved asset (Reuters)
Positive Phase 2b data for TPIP in pulmonary arterial hypertension met all primary and secondary endpoints and drove a 28% stock rally, underlining market confidence in the drug’s once-daily differentiated profile (Barron’s)
Brinsupri’s annual list price of $88,000 may trigger payer resistance and restrict patient access, potentially capping initial market uptake and revenue growth (Reuters)
Brensocatib will enter a competitive landscape with late-stage candidates from AstraZeneca and Zambon targeting bronchiectasis, risking pricing pressure and share erosion (Reuters)
Insmed reported a net loss of $321.7 million in Q2 2025 and $578.3 million for the first half of 2025, underscoring high cash burn and dependence on external financing to fund ongoing R&D (SEC Form 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
Insmed Financial Performance
Revenues and expenses
Insmed Earnings Performance
Company profitability
Insmed News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Insmed stock?
Insmed (INSM) has a market cap of $40B as of November 04, 2025.
What is the P/E ratio for Insmed stock?
The price to earnings (P/E) ratio for Insmed (INSM) stock is 0 as of November 04, 2025.
Does Insmed stock pay dividends?
No, Insmed (INSM) stock does not pay dividends to its shareholders as of November 04, 2025.
When is the next Insmed dividend payment date?
Insmed (INSM) stock does not pay dividends to its shareholders.
What is the beta indicator for Insmed?
Insmed (INSM) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.